Sangamo Therapeutics (SGMO)

$0.11 -0.07 (-37.27%)
Market Cap 73.58M
Revenue (ttm) 39.55M
Net Income (ttm) -122.93M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -310.82%
Debt to Equity Ratio 0.00
Volume 44,541,699
Avg Vol 10,731,998
Day's Range N/A - N/A
Shares Out 414.28M
Stochastic %K 4%
Beta 1.04
Analysts Sell
Price Target $3.75

Company Profile

Sangamo Therapeutics, Inc., a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; small fiber neuropathy for chronic neuropathic pain, and prion disease; Phase 1/2 clinical trial to evaluate the...

Industry: Biotechnology
Sector: Healthcare
Phone: 510 970 6000
Address:
501 Canal Blvd, Richmond, United States
biotech
biotech Aug. 19 at 3:35 PM
$SGMO $SGMO On behalf of the #equity #holders, it is requested that consideration be made that the sale of the Merope ($LLY) by Sangamo be #terminated ... https://www.veritaglobal.net/sangamotherapeutics/document/2610989260819000000000001
0 · Reply
Chipoo
Chipoo Aug. 19 at 3:30 PM
$SGMO GOD BLESS FRANK FOLEY whoever you are! Just hit the docket.
2 · Reply
greko50
greko50 Aug. 19 at 2:06 PM
$SGMO I believe the market is pricing a little uncertainty around the Merope asset sale closing as planned tomorrow, hence why our sp remains somewhat suppressed. If the deal goes through as planned, I believe we'll move higher towards .20, and then the main focus for me at least is the remaining bucket of assets and the $100 mil milestone payment. Both of those can only add equity, as I believe neither one has been baked in whatsoever.....
2 · Reply
Chipoo
Chipoo Aug. 19 at 12:22 PM
$SGMO Does the committee Scooter is on have an objection to the sales yet? If not, getting more concerned.
1 · Reply
JimiJoJeeter
JimiJoJeeter Aug. 19 at 12:04 PM
$SGMO So, my thanks to all here for the information and clarifying opinions. You all need a good laugh....
0 · Reply
IberianBullish
IberianBullish Aug. 19 at 11:55 AM
$SGMO@greko50 I agree with what Docket 326 actually says: no competing Qualified Bid was submitted, the bidders were given a final opportunity to bid, and the Equity Committee was consulted before the Merope auction was closed. Those are facts. But I think there is still one very important unanswered question: WHY was there no competing Qualified Bid? Now that Genentech, Astellas and Alexion are all disputing what rights Lilly can actually acquire “free and clear,” we have to ask whether that uncertainty affected the bidding process. Did potential bidders decline to bid, or decline to qualify a bid, because the scope of the IP/licensing rights being sold was unclear? If the answer is no, then $50M may indeed be the best market evidence we have. But if the answer is yes, then the absence of an overbid does not necessarily establish that $50M represents the value of Merope under clarified rights. That, in my opinion, is one of the key questions for the hearing.
2 · Reply
OracleofOntario
OracleofOntario Aug. 19 at 11:40 AM
$SGMO while it has happened, I don't think the judge will vacate the sale order in this case. We'll see.
1 · Reply
ican
ican Aug. 19 at 10:42 AM
$SGMO https://x.com/BiotechAnalysst/status/2089964673831457184
0 · Reply
ican
ican Aug. 19 at 10:41 AM
$SGMO https://x.com/Franca_ole/status/2089949965791469715
0 · Reply
ican
ican Aug. 19 at 10:39 AM
$SGMO this is what I am thinking about any potential carve outs: https://x.com/BiotechAnalysst/status/2089813884123193652
0 · Reply
Latest News on SGMO
No data available.
biotech
biotech Aug. 19 at 3:35 PM
$SGMO $SGMO On behalf of the #equity #holders, it is requested that consideration be made that the sale of the Merope ($LLY) by Sangamo be #terminated ... https://www.veritaglobal.net/sangamotherapeutics/document/2610989260819000000000001
0 · Reply
Chipoo
Chipoo Aug. 19 at 3:30 PM
$SGMO GOD BLESS FRANK FOLEY whoever you are! Just hit the docket.
2 · Reply
greko50
greko50 Aug. 19 at 2:06 PM
$SGMO I believe the market is pricing a little uncertainty around the Merope asset sale closing as planned tomorrow, hence why our sp remains somewhat suppressed. If the deal goes through as planned, I believe we'll move higher towards .20, and then the main focus for me at least is the remaining bucket of assets and the $100 mil milestone payment. Both of those can only add equity, as I believe neither one has been baked in whatsoever.....
2 · Reply
Chipoo
Chipoo Aug. 19 at 12:22 PM
$SGMO Does the committee Scooter is on have an objection to the sales yet? If not, getting more concerned.
1 · Reply
JimiJoJeeter
JimiJoJeeter Aug. 19 at 12:04 PM
$SGMO So, my thanks to all here for the information and clarifying opinions. You all need a good laugh....
0 · Reply
IberianBullish
IberianBullish Aug. 19 at 11:55 AM
$SGMO@greko50 I agree with what Docket 326 actually says: no competing Qualified Bid was submitted, the bidders were given a final opportunity to bid, and the Equity Committee was consulted before the Merope auction was closed. Those are facts. But I think there is still one very important unanswered question: WHY was there no competing Qualified Bid? Now that Genentech, Astellas and Alexion are all disputing what rights Lilly can actually acquire “free and clear,” we have to ask whether that uncertainty affected the bidding process. Did potential bidders decline to bid, or decline to qualify a bid, because the scope of the IP/licensing rights being sold was unclear? If the answer is no, then $50M may indeed be the best market evidence we have. But if the answer is yes, then the absence of an overbid does not necessarily establish that $50M represents the value of Merope under clarified rights. That, in my opinion, is one of the key questions for the hearing.
2 · Reply
OracleofOntario
OracleofOntario Aug. 19 at 11:40 AM
$SGMO while it has happened, I don't think the judge will vacate the sale order in this case. We'll see.
1 · Reply
ican
ican Aug. 19 at 10:42 AM
$SGMO https://x.com/BiotechAnalysst/status/2089964673831457184
0 · Reply
ican
ican Aug. 19 at 10:41 AM
$SGMO https://x.com/Franca_ole/status/2089949965791469715
0 · Reply
ican
ican Aug. 19 at 10:39 AM
$SGMO this is what I am thinking about any potential carve outs: https://x.com/BiotechAnalysst/status/2089813884123193652
0 · Reply
greko50
greko50 Aug. 19 at 9:54 AM
$SGMO Here is paragraph #9 from docket #326. We can sit here and speculate on maybe why there wasn't any other interest in the assets, but the facts are they received no other qualified bids prior to the auction, and then even during the auction there were qualified bidders that had an opportunity to bid and still chose not to bid higher than the $50 mil stalking horse bid. Not only is RJ advisor approving this sale, our very own equity committee is also.
2 · Reply
ican
ican Aug. 19 at 2:56 AM
$SGMO ok so now , The following documents were filed with the court: 8/7 Genetech's objection to approving sale of IP assets, and authorizing rejection of executory contracts -270 8/17 Astellas limited objection to sale of certain assets to Merope stalking horse bidder free...-308 8/17 Alexion limited objection to sale of certain assets to Stalking Horse bidder ... -309 8/17 Astellas limited objection to debtors sale motion - 319 8/17 Alexion limited objection to debtors sale motion -320 8/18 Joinder and limited objection of Shire Human Genetics of Alexion to debtors proposed sale of certain assets - 331 Shire seems new to me Lots of motions here - just my opinion , maybe the side deals may not be working out?
1 · Reply
steven1x
steven1x Aug. 18 at 11:50 PM
$SGMO if bankruptcy who gets the money ? https://www.cellgenetherapyreview.com/3972-News/627428-Lilly-PTC-pick-up-Sangamo-gene-therapies-in-bankruptcy-auction/
0 · Reply
Herr_Chicken
Herr_Chicken Aug. 18 at 10:59 PM
$SGMO Looks like August 20, 10 AM, there's gonna be a rumble ...
2 · Reply
Patrick2343
Patrick2343 Aug. 18 at 9:45 PM
$SGMO Doesnt the next aunction need to happy fairly soon to meet the court schedules?
0 · Reply
Imv85
Imv85 Aug. 18 at 8:39 PM
$SGMO not sure this is correct. The docket at pages 3-4 lists comments and objections ahead of the hearing (items A to H). Objections are items B to F. Only item D has been settled, so objections B (genetech), C (Catalent), E (Astellas) and F (Alexion) are at the moment not settled and need to be discussed at the hearing.
2 · Reply
ican
ican Aug. 18 at 7:24 PM
$SGMO I see Lily just got a lawyer admission and access - Jeffrey J Recher - Doc 329.
0 · Reply
Jeffkad
Jeffkad Aug. 18 at 6:56 PM
$SGMO with major props to greko50, here’s our worst case scenario at .20, with base case at .40. Time for sp to bubble back up over .20
0 · Reply
Jeffkad
Jeffkad Aug. 18 at 6:51 PM
$SGMO now we should go back to at least .20-.22 until the other assets are sold.
0 · Reply
greko50
greko50 Aug. 18 at 6:05 PM
$SGMO Docket 326 just hit the wires from Raymond James and Merope is basically settled at $50M + assumed liabilities. Unless the court finds some legal problem with the transaction, Docket 326 is strong evidentiary support for approval...... I know some were wanting a different outcome but its basically over now, time to concentrate on remaining bucket of assets and the $100 mil milestone payment, along with what our liabilities will ultimately be.....
5 · Reply
Jeffkad
Jeffkad Aug. 18 at 3:18 PM
$SGMO am I wrong to suggest maybe we should wish they leave the auction results alone, take the $50M, and move on to remaining asset sale? I don’t like prospect of taking $50M off the table and hoping there might magically be another bidder for this merope asset when there wasn’t before?
3 · Reply
bavariaron
bavariaron Aug. 18 at 1:22 PM
$SGMO ** Partial Objection Precedents ** One Potential outcome out of many… QUOTE Yes, there is legal precedent where a bankruptcy judge has modified or limited the scope of a Chapter 11 asset sale or auction to prevent it from wiping away a licensee's statutory protections under Section 365(n) of the Bankruptcy Code. Rather than completely scrap a multi-million-dollar auction, bankruptcy judges typically handle partial objections by refusing to confirm the sale "free and clear" of those specific license rights. The court will carve out the licensee’s rights from the final sale order. UNQUOTE
5 · Reply